Pandion unveils new data to back up strategy of activating PD-1 to treat autoimmune diseases

Stomach with colon
One of Pandion's drug candidates, PT001, was engineered to selectively activate PD-1 in the gut. (peterschreiber.media/Getty Images)

Inhibiting the immune checkpoint protein PD-1 to combat tumors is the basis of several successful immuno-oncology drugs, including Merck’s Keytruda. But those drugs are known to raise the risk of some autoimmune diseases, such as colitis.

Startup Pandion Therapeutics is taking that risk and turning it into an opportunity—creating drugs that activate PD-1 instead of inhibiting it in the hopes of addressing several autoimmune diseases. It presented preclinical data on several of those drugs at the virtual meeting of the Federation of Clinical Immunology Societies (FOCIS).

One of the drugs, dubbed PT001, was engineered to selectively activate PD-1 in the gut. In a preclinical study, Pandion demonstrated that PT001 activated PD-1 there without blocking the normal receptor. In animal models of graft-versus-host disease, the drug prolonged survival, according to the presentation (PDF).

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Pandion, a 2018 Fierce 15 selection, raised $80 million in April of this year to drive its lead candidate, PT-101 for ulcerative colitis, through clinical trials. It brought in $135 million in an initial public offering in July, outpacing its initial fundraising goal of $75 million.

Pandion’s specialty is “modular” drug design, an engineering process it uses to tether therapeutics to tissue-targeted molecules. PT-101 combines interleukin-2 with a protein designed to expand disease-fighting T cells without activating other immune cells that cause inflammation.

RELATED: Pandion Therapeutics scores $80M to drive autoimmune programs through clinic

PT-001 is a PD-1 agonist tethered to a gut-targeted molecule Pandion calls MAdCAM. The company is developing the drug to treat autoimmune diseases of the gastrointestinal tract and liver.

During FOCIS, Pandion unveiled details about other preclinical programs in the works. The company created an IL-2 drug that’s tethered to a kidney-targeted molecule. It’s now investigating the approach to treat inflammatory conditions of the kidney, it said.

It also created a PD-1 activator that’s tethered to the skin. In an animal model of vitiligo, that drug reduced the skin-lightening effects of the disease without affecting normal immune cells, the company said.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.